Akebia Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Akebia Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Akebia Therapeutics Inc Strategy Report
- Understand Akebia Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Akebia Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Akebia Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 27 Aug 2020 | Lorem |
| AstraZeneca/FibroGen’s roxadustat has nebulous future under CMS payment structure for CKD dialysis patients; eventual use as part of bundle faces fiscal challenges, experts say | 26 Aug 2020 | Manasi Vaidya |
| Akebia’s vadadustat uptake in DD-CKD patients limited to high-dose ESA niche, but could improve with dosing schedule improvements | 25 Nov 2019 | Manasi Vaidya |
| Akebia’s vadadustat finds uphill challenge to get safety label sans black box warning contrary to AstraZeneca/FibroGen's roxadustat in CKD; pause on Japanese data extrapolation, experts say | 21 Nov 2019 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer